Literature DB >> 10543888

Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.

S M Husbands1, S Izenwasser, T Kopajtic, W D Bowen, B J Vilner, J L Katz, A H Newman.   

Abstract

9-[3-(cis-3,5-Dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) has been characterized as a sigma receptor antagonist that binds to the dopamine transporter with moderate affinity (K(i) = 224 nM). Although the binding affinities at the dopamine transporter of rimcazole and cocaine are comparable, rimcazole only depressed locomotor activity in mice and antagonized the stimulant effects produced by cocaine. The neurochemical mechanisms underlying the attenuation of cocaine's effects are not understood, although interaction at a low affinity site/state of the dopamine transporter has been suggested. To explore further this class of compounds, a series of rimcazole analogues was designed and synthesized. Displacement of [(3)H]WIN 35,428 binding at the dopamine transporter in rat caudate-putamen revealed that aromatic substitutions on rimcazole were not well tolerated, generally, with significant reductions in affinity for the 3,6-dibromo (5; K(i) = 3890 nM), 1,3, 6-tribromo (6; K(i) = 30300 nM), 3-amino (8; K(i) = 2400 nM), and 3, 6-dinitro (9; K(i) = 174000 nM) analogues. The N-phenylpropyl group was the only terminal piperazine nitrogen substituent that retained moderate affinity at the dopamine transporter (11; K(i) = 263 nM). Analogues in which the carbazole ring was replaced with a freely rotating diphenylamine moiety were also prepared. Although the diphenylamino analogue in which the terminal piperazine nitrogen was unsubstituted, as in rimcazole, demonstrated relatively low binding affinity at the dopamine transporter (24; K(i) = 813 nM), the N-phenylpropyl analogue was found to have the highest affinity for the dopamine transporter within the series (25; K(i) = 61.0 nM). All of the analogues that had affinity for the dopamine transporter inhibited [(3)H]dopamine uptake in synaptosomes, and potencies for these two effects showed a positive correlation (r(2) = 0.7731, p = 0.0018). Several of the analogues displaced [(3)H]paroxetine from serotonin transporters with moderate to high affinity, with the N-phenylpropyl derivative (11) having the highest affinity (K(i) = 44.5 nM). In contrast, none of the analogues recognized the norepinephrine transporter with an affinity of <1.3 microM. Binding affinities for sigma(1) and sigma(2) receptors were also determined, and several of the compounds were more potent than rimcazole with affinities ranging from 97 nM to >6 microM at sigma(1) sites and 145 to 1990 nM at sigma(2) sites. The compound with the highest affinity (25) at sigma(1) sites was also the compound with highest affinity at the dopamine transporter. These novel rimcazole analogues may provide important tools with which to characterize the relationship between the low affinity site or state of the dopamine transporter, sigma receptors, and their potential roles in modulating cocaine's psychostimulant actions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543888     DOI: 10.1021/jm9902943

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

Review 1.  The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.

Authors:  Danielle O Sambo; Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Pharmacol Ther       Date:  2018-01-31       Impact factor: 12.310

2.  Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and σ receptors.

Authors:  Takato Hiranita; Paul L Soto; Stephen J Kohut; Theresa Kopajtic; Jianjing Cao; Amy H Newman; Gianluigi Tanda; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2011-08-22       Impact factor: 4.030

3.  Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): effects on binding affinity and selectivity for sigma receptors and monoamine transporters.

Authors:  Rong Xu; Sarah A Lord; Ryan M Peterson; Emily A Fergason-Cantrell; John R Lever; Susan Z Lever
Journal:  Bioorg Med Chem       Date:  2014-11-11       Impact factor: 3.641

4.  2-isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter.

Authors:  Takato Hiranita; Derek S Wilkinson; Weimin C Hong; Mu-Fa Zou; Theresa A Kopajtic; Paul L Soto; Carl R Lupica; Amy H Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2014-02-11       Impact factor: 4.030

5.  Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors.

Authors:  Jianjing Cao; Rachel D Slack; Oluyomi M Bakare; Caitlin Burzynski; Rana Rais; Barbara S Slusher; Theresa Kopajtic; Alessandro Bonifazi; Michael P Ellenberger; Hideaki Yano; Yi He; Guo-Hua Bi; Zheng-Xiong Xi; Claus J Loland; Amy Hauck Newman
Journal:  J Med Chem       Date:  2016-11-28       Impact factor: 7.446

6.  Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol.

Authors:  Jianjing Cao; Theresa Kopajtic; Jonathan L Katz; Amy Hauck Newman
Journal:  Bioorg Med Chem Lett       Date:  2008-08-22       Impact factor: 2.823

7.  Irreversible binding of a novel phenylisothiocyanate tropane analog to monoamine transporters in rat brain.

Authors:  Vishakantha Murthy; Huw M L Davies; Simon J Hedley; Steven R Childers
Journal:  Biochem Pharmacol       Date:  2007-04-27       Impact factor: 5.858

8.  New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders.

Authors:  Amy Hauck Newman; Therese Ku; Chloe J Jordan; Alessandro Bonifazi; Zheng-Xiong Xi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2021-01-06       Impact factor: 16.459

Review 9.  Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?

Authors:  José Miguel Vela
Journal:  Front Pharmacol       Date:  2020-11-09       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.